The US FDA has recently given a priority review designation for Dalteparin Sodium injectable for treating potentially life-threatening disease. The first anticoagulant injectable is approved for symptomatic venous thromboembolism (VTE) for pediatric patients with the age of 1 month or older. VTE is a specialized blood clot in the deep veins known as vein thrombosis and a blood clot in the lungs is known as pulmonary embolism.
Children suffering from VTE have chances of attaining co-morbidities such as Cancer Congenital heart disease Cardiovascular dysfunctions Venous catheter Recurrent VTE Post-thrombotic syndrome Drug Information: Parameter Dalteparin General Description It is the type of a low molecular weight fractionated heparin, which is composed of strongly acidic sulphated polysaccharide chains. It is formed when nitrous acid at porcine intestinal mucosa origin degrades.…
